by The global Immunohistochemistry market size is expected to be worth around US$ 5.07 billion by 2030, according to a new report by Vision Research Reports.
The global Immunohistochemistry market size was valued at US$ 2.28 billion in 2020 and is anticipated to grow at a CAGR of 7.2% during forecast period 2021 to 2030.
Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/39077
Growth Factors
The high demand for accurate data has driven several technological advancements in (immunohistochemistry) IHC techniques, resulting in the delivery of precise and contextual data analyses. The emergence of various advanced techniques, such as multiplex IHC, computational pathology, and next-generation IHC, is driving the market for immunohistochemistry.
IHC protocols have gained popularity in the field of clinical pathology, especially in the subspecialties of oncologic pathology, hematopathology, and neuropathology. The technique has played a vital role in shaping cancer diagnostics. Thus, the growing prevalence of cancer is expected to increase the demand for immunohistochemistry, thus contributing to market growth.
Report Coverage
| Report Scope | Details |
| Market Size | US$ 5.07 billion by 2030 |
| Growth Rate | CAGR of 7.2% From 2021 to 2030 |
| Largest Market | North America |
| Base Year | 2021 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Product, Application, End-use |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Mentioned | Thermo Fisher Scientific Inc.; F. Hoffmann-La Roche Ltd.; Merck KGaA; Danaher Corporation; PerkinElmer, Inc.; Bio-Rad Laboratories, Inc.; Cell Signaling Technology, Inc.; Bio SB; Abcam plc.; Agilent Technologies, Inc. |
By Product Analysis
The antibodies segment captured the largest revenue share of over 30.0% in 2020 owing to the vital usage of antibodies in disease diagnosis and drug testing. The monoclonal antibodies and antibody-related products such as Fc-fusion, antibody fragments, and antibody-drug conjugates have become the dominating product class in terms of usage rate.
Kits are anticipated to expand at the fastest CAGR throughout the forecast period. The use of kits reduces a lot of efforts during the IHC procedure as it eliminates the selection procedure for use of an appropriate combination of antibodies and stains against a tissue sample.
By Application Analysis
The diagnostics segment accounted for the largest revenue share of over 50.0% in 2020 and is anticipated to maintain its lead over the forecast period. Immunohistochemistry (IHC) tests are widely used for the diagnosis of a wide range of chronic conditions, such as cancer, cardiovascular diseases, infectious diseases, diabetes mellitus, autoimmune diseases, and nephrological diseases.
The growing prevalence of chronic diseases is anticipated to drive the diagnostics segment. According to data published by the American Cancer Society, around 1.9 million new cancer cases are expected to be reported in the U.S. in 2021. With a rise in the number of cancer cases, the need for IHC techniques for rapid and efficient diagnosis is high.
Thus, rising R&D activities by pharmaceutical companies for research and development of innovative drugs are anticipated to increase the demand for IHC solutions and drive the segment.
By End-use Analysis
Hospitals and diagnostic laboratories accounted for the largest revenue share of over 50.0% owing to the high volume of IHC tests carried out in hospitals settings. Furthermore, with the constant changes in the healthcare industry, the need for hospitals with advanced facilities has also increased, which is expected to drive the revenue flow in this segment.
Research institutes are expected to register a lucrative CAGR during the forecast period. This is because the technique offers several advantages over conventionally used staining techniques in pharmaceutical R&D.
The growth can be also attributed to the wide adoption of IHC techniques in drug testing by research institutes. The technique allows the evaluation of biomarker distribution and localization and different protein expressions in varied biological tissue sections, which is conducted in research settings.
By Regional Analysis
North America dominated the market in 2020 with a revenue share of over 45.0%. Key factors contributing to the regional market growth include the local presence of major market players, easy availability of IHC solutions, higher adoption of technologically advanced IHC instruments, and entry of newer IHC solutions.
Asia Pacific is expected to witness the fastest growth during the forecast period. This is primarily due to the expansion of the geographic footprint of the global players in the Asian markets.
Key Players
- Thermo Fisher Scientific Inc.
- F. Hoffmann-La Roche Ltd.
- Merck KGaA
- Danaher Corporation
- Perkinelmer, Inc.
- Bio-Rad Laboratories, Inc.
- Cell Signaling Technology, Inc.
- Bio SB
- Agilent Technologies, Inc.
- Abcam plc.
Market Segmentation
- By Product
- Antibodies
- Primary Antibodies
- Secondary Antibodies
- Equipment
- Slide Staining System
- Tissue Microarrays
- Tissue Processing Systems
- Slide Scanners
- Others
- Reagents
- Histological stains
- Blocking Sera and Reagents
- Chromogenic Substrates
- Fixation Reagents
- Stabilizers
- Organic Solvents
- Proteolytic Enzymes
- Diluents
- Kits
- Antibodies
- By Application
- Diagnostics
- Cancer
- Infectious Diseases
- Cardiovascular Diseases
- Autoimmune Diseases
- Diabetes Mellitus
- Nephrological Diseases
- Drug Testing
- Diagnostics
- by End-use
- Hospitals & Diagnostic Laboratories
- Research Institutes
- Others
- Regional
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Asia Pacific
- Japan
- China
- India
- South Korea
- Australia
- Singapore
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- North America
Table of Contents
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Immunohistochemistry Market, By Product
7.1. Immunohistochemistry Market, by Product, 2021-2030
7.1.1. Antibodies
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. Equipment
7.1.2.1. Market Revenue and Forecast (2017-2030)
7.1.3. Reagents
7.1.3.1. Market Revenue and Forecast (2017-2030)
7.1.4. Kits
7.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 8. Global Immunohistochemistry Market, By Application
8.1. Immunohistochemistry Market, by Application, 2021-2030
8.1.1. Diagnostics
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Drug Testing
8.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Immunohistochemistry Market, By End User
9.1. Immunohistochemistry Market, by End User, 2021-2030
9.1.1. Hospitals & Diagnostic Laboratories
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Research Institutes
9.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Immunohistochemistry Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Product (2017-2030)
10.1.2. Market Revenue and Forecast, by Application (2017-2030)
10.1.3. Market Revenue and Forecast, by End User (2017-2030)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.1.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.1.4.3. Market Revenue and Forecast, by End User (2017-2030)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.1.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.1.5.3. Market Revenue and Forecast, by End User (2017-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.2. Market Revenue and Forecast, by Application (2017-2030)
10.2.3. Market Revenue and Forecast, by End User (2017-2030)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.2.4.3. Market Revenue and Forecast, by End User (2017-2030)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.2.5.3. Market Revenue and Forecast, by End User (2017-2030)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.6.2. Market Revenue and Forecast, by Application (2017-2030)
10.2.6.3. Market Revenue and Forecast, by End User (2017-2030)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, by Product (2017-2030)
10.2.7.2. Market Revenue and Forecast, by Application (2017-2030)
10.2.7.3. Market Revenue and Forecast, by End User (2017-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.2. Market Revenue and Forecast, by Application (2017-2030)
10.3.3. Market Revenue and Forecast, by End User (2017-2030)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.3.4.3. Market Revenue and Forecast, by End User (2017-2030)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.3.5.3. Market Revenue and Forecast, by End User (2017-2030)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.6.2. Market Revenue and Forecast, by Application (2017-2030)
10.3.6.3. Market Revenue and Forecast, by End User (2017-2030)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, by Product (2017-2030)
10.3.7.2. Market Revenue and Forecast, by Application (2017-2030)
10.3.7.3. Market Revenue and Forecast, by End User (2017-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.4.3. Market Revenue and Forecast, by End User (2017-2030)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.4.4.3. Market Revenue and Forecast, by End User (2017-2030)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.4.5.3. Market Revenue and Forecast, by End User (2017-2030)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.6.2. Market Revenue and Forecast, by Application (2017-2030)
10.4.6.3. Market Revenue and Forecast, by End User (2017-2030)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, by Product (2017-2030)
10.4.7.2. Market Revenue and Forecast, by Application (2017-2030)
10.4.7.3. Market Revenue and Forecast, by End User (2017-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.5.3. Market Revenue and Forecast, by End User (2017-2030)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, by Product (2017-2030)
10.5.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.5.4.3. Market Revenue and Forecast, by End User (2017-2030)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, by Product (2017-2030)
10.5.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.5.5.3. Market Revenue and Forecast, by End User (2017-2030)
Chapter 11. Company Profiles
11.1. Thermo Fisher Scientific Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. F. Hoffmann-La Roche Ltd.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Merck KGaA
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Danaher Corporation
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Perkinelmer, Inc.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Bio-Rad Laboratories, Inc.
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Cell Signaling Technology, Inc.
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Bio SB
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Agilent Technologies, Inc.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Abcam plc.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/39077
Contact Us:
Vision Research Reports
Call: +1 9197 992 333
